Chronic Obstructive Pulmonary Disease Clinical Trials

Recruiting Chronic Obstructive Pulmonary Disease studies

• Emphysema Research Registry and Biosample Repository
  NCT00307281University of PittsburghEmphysemaPittsburgh, Pennsylvania
• Evaluation of the Paramedic Evaluation for Acute COPD Exacerbation
  NCT07072039NAUniversity of Massachusetts, WorcesterCOPD (Chronic Obstructive Pulmonary Disease)Worcester, Massachusetts
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966PHASE3AstraZenecaCOPD (Chronic Obstructive Pulmonary Disease)Athens, Alabama
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222PHASE3SanofiChronic Obstructive Pulmonary DiseaseBirmingham, Alabama
• To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
  NCT07684820PHASE2Expedition Therapeutics, IncChronic Obstructive Pulmonary Disease (COPD)Phoenix, Arizona
• Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
  NCT05934565NABeth Israel Deaconess Medical CenterChronic Obstructive Pulmonary DiseaseBoston, Massachusetts
• : Vascular Function in Health and Disease
  NCT02966665PHASE1D. Walter WrayChronic Obstructive Pulmonary DiseaseSalt Lake City, Utah
• A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
  NCT07725939PHASE2UCB Biopharma SRLChronic Obstructive Pulmonary Disease With Chronic BronchitisColumbus, Ohio
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
  NCT07190209PHASE3SanofiChronic Obstructive Pulmonary DiseaseChandler, Arizona
• A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
  NCT07053423PHASE4SanofiChronic Obstructive Pulmonary DiseaseBirmingham, Alabama
• A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)
  NCT07793409PHASE3SanofiChronic Obstructive Pulmonary DiseaseNewport Beach, California
• A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
  NCT07646587PHASE2Windward BioCOPD (Chronic Obstructive Pulmonary Disease)Los Angeles, California

See all 50 recruiting trials →

Chronic Obstructive Pulmonary Disease trials by state

• California
• Texas
• New York
• Florida
• Pennsylvania
• Massachusetts
• Ohio
• Illinois
• North Carolina
• Maryland
• Georgia
• Tennessee

Chronic Obstructive Pulmonary Disease trials by metro

• New York
• Houston
• Boston
• Chicago
• Philadelphia
• Los Angeles
• Dallas
• Atlanta
• Miami
• Nashville
• Rochester
• Baltimore

Frequently asked questions

How do I find recruiting Chronic Obstructive Pulmonary Disease clinical trials?

Browse the actively recruiting Chronic Obstructive Pulmonary Disease studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.

Are Chronic Obstructive Pulmonary Disease clinical trials free to join?

Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.

Who can take part in a Chronic Obstructive Pulmonary Disease clinical trial?

Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.